MedTrace Logo

A Phase 2 Trial Investigating the Safety, Tolerability and Efficacy of EXT608 in Adults With Hypoparathyroidism

NCT06988670 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2025-05-25

No results posted yet for this study

Summary

The goal of this clinical trial is to investigate the safety, tolerability and efficacy of EXT608 in adults with hypoparathyroidism.

Conditions

  • Hypoparathyroidism

Interventions

DRUG

EXT608

Modified version of parathyroid hormone attached to vitamin D to extend half-life

OTHER

Placebo

Placebo for injection

Sponsors & Collaborators

  • Extend Biosciences Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-05
Primary Completion
2027-05-31
Completion
2027-05-31
FDA Drug
Yes

Countries

  • Argentina

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06988670 on ClinicalTrials.gov